Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Especificación
Tipo de cuenta
Investing: Web
Investing: Web
Comisiones
0.006USD
Horario de operaciones (UTC)
Abrir ahoraCerradoCierre elApertura el
a las
-
El horario de apertura del mercado se indica según su zona horaria local
(UTC)
Abre una cuenta y comienza a invertir con Metadoro ahora. Invite a amigos y obtenga remuneración por su comercio activo. Puede obtener más información sobre el programa de afiliados en su Área Personal.
Gracias por visitarnos metadoro.com. Este sitio web es administrado por RHC Investments, que está autorizada y regulada como Agente de Inversiones por la Comisión de Servicios Financieros de Mauricio con el número de licencia C115015381. Mauricio no forma parte del marco regulatorio europeo y no está dentro del alcance (entre otros) de la Directiva sobre Mercados de Instrumentos Financieros (MiFID) II.
Al continuar, confirma que la decisión se toma de forma independiente y por iniciativa propia y exclusiva y que RHC Investments no ha realizado ninguna solicitud o recomendación.
¡Personalice la suscripción a su manera!Create a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Detección oportuna de altibajos del mercado, fluctuaciones, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found